Trials / Unknown
UnknownNCT04045171
Population Pharmacokinetics of Tacrolimus in Nephrotic Syndrome
Population Pharmacokinetics of Tacrolimus for Optimal Dose in Patients With Nephrotic Syndrome
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- The Third Xiangya Hospital of Central South University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will use a multi-center, prospective design, with a "Real World Study" model, to include 200 patients with nephrotic syndrome. based on the Population Pharmacokinetics (PPK) model, it will study genotype and clinical factors in patients with nephrotic syndrome, to explore the Pharmacokinetics/ Pharmacodynamics (PK/PD) relationship of Tacrolimus in patients with nephrotic syndrome, and develop an optimal medication regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tacrolimus | Tacrolimus, oral, 0.05-0.075 mg/kg/d, Q12h, 6～12 months |
Timeline
- Start date
- 2019-08-10
- Primary completion
- 2020-07-31
- Completion
- 2020-12-31
- First posted
- 2019-08-05
- Last updated
- 2019-08-05
Source: ClinicalTrials.gov record NCT04045171. Inclusion in this directory is not an endorsement.